Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial

Sweet, Kristen; Dasgupta, B.; Vries, Dick de; Gourley, Ian; Hsu, Benjamin; Loza, Matthew; Taylor, Peter C

doi:10.1136/annrheumdis-2019-215183

Cited by 3 publications

(1 citation statement)

References 4 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is important to take clinical context into account when interpreting ultrasonographic findings. For example, low grade vascular signal is commonplace in patients with concomitant osteoarthritis and not all patients meeting composite criteria for active disease have ultrasound evidence of power Doppler signal [46]. It has been argued that treating to a target of ultrasonographic imaging remission might afford tighter disease control and therefore better clinical and radiographic outcomes than treating to a remission target defined by composite clinical scores.…”

Section: The Role Of Ultrasound Assessment Of Established Ra Bmentioning

confidence: 99%

When the first visit to the rheumatologist is established rheumatoid arthritis

Taylor

Law

2019

Best Practice & Research Clinical Rheumatology

View full text Add to dashboard Cite

The outlook for people living with rheumatoid arthritis has improved tremendously in a generation.Major contributions to this include recognition of the importance of early treatment initiation, improved understanding of the pathobiology, identification of therapeutic targets and their subsequent validation in clinic trials; and the realisation of the importance of "tight control" of inflammatory responses. Despite these advances, many patients meeting classification criteria present for the first time to a rheumatologist with longstanding symptoms. There is no definition as to when rheumatoid arthritis becomes "established". But there is evidence that a "window of opportunity" exists over about 12-16 weeks symptom duration during which treatment intervention gives rise to the most optimal outcomes. This review addresses issues regarding management of patients presenting outside the window of opportunity in terms of heterogeneity of presentation, assessment, therapeutic goals and treatment options as well as the importance of a multidisciplinary approach to holistic care.

show abstract

Section: The Role Of Ultrasound Assessment Of Established Ra Bmentioning

confidence: 99%

When the first visit to the rheumatologist is established rheumatoid arthritis

Taylor

Law

2019

Best Practice & Research Clinical Rheumatology

View full text Add to dashboard Cite

show abstract

Antibody drugs targeting SARS-CoV-2: Time for a rethink?

Liang,

Wang,

Zhang

et al. 2024

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

The JAK-STAT pathway: from structural biology to cytokine engineering

Lv,

Qi,

Babon

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway serves as a paradigm for signal transduction from the extracellular environment to the nucleus. It plays a pivotal role in physiological functions, such as hematopoiesis, immune balance, tissue homeostasis, and surveillance against tumors. Dysregulation of this pathway may lead to various disease conditions such as immune deficiencies, autoimmune diseases, hematologic disorders, and cancer. Due to its critical role in maintaining human health and involvement in disease, extensive studies have been conducted on this pathway, ranging from basic research to medical applications. Advances in the structural biology of this pathway have enabled us to gain insights into how the signaling cascade operates at the molecular level, laying the groundwork for therapeutic development targeting this pathway. Various strategies have been developed to restore its normal function, with promising therapeutic potential. Enhanced comprehension of these molecular mechanisms, combined with advances in protein engineering methodologies, has allowed us to engineer cytokines with tailored properties for targeted therapeutic applications, thereby enhancing their efficiency and safety. In this review, we outline the structural basis that governs key nodes in this pathway, offering a comprehensive overview of the signal transduction process. Furthermore, we explore recent advances in cytokine engineering for therapeutic development in this pathway.

show abstract

Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial

Cited by 3 publications

References 4 publications

When the first visit to the rheumatologist is established rheumatoid arthritis

When the first visit to the rheumatologist is established rheumatoid arthritis

Antibody drugs targeting SARS-CoV-2: Time for a rethink?

The JAK-STAT pathway: from structural biology to cytokine engineering

Contact Info

Product

Resources

About